Can Kānuka Leaf Extract Bridge the Gap Between Deodorant and Antiperspirant? A KanuFresh Evidence Audit

Why this launch matters

On 18 September 2026, Lucas Meyer Cosmetics by Clariant launched KanuFresh, a cosmetic active with the INCI name Glycerin (and) Water (and) Kunzea Ericoides Leaf Extract. The supplier positions it for aluminium-free deodorant innovation and says it is natural-origin, COSMOS-compliant, vegan, halal and compatible with major markets. Those facts establish a commercially important ingredient launch; they do not by themselves establish that every finished product containing it will control sweat or odour.

The commercial signal is strong because deodorant brands are looking for language between simple fragrance masking and regulated antiperspirant performance. KanuFresh is therefore relevant to formulators and retailers, but LifeCareYou treats the launch as product intelligence, not a recommendation to buy.

What the supplier reports

Clariant reports reductions of up to 54% in visible signs of perspiration, 44% in odour intensity and 35% in irritation, with benefits lasting up to 24 hours. It says tests covered hands and underarms, women and men, Fitzpatrick I–VI phototypes, stress and physical-activity conditions.

Important details are not disclosed in the public release: sample size, active concentration, vehicle formula, comparator or placebo, measurement instruments, statistical analysis, adverse events and a peer-reviewed protocol. The percentages are therefore supplier-reported findings, not independently verified clinical outcomes.

Deodorant is not automatically antiperspirant

The FDA’s OTC Monograph M019 defines the United States antiperspirant framework and lists aluminium or aluminium-zirconium active compounds with specified concentrations. Kānuka leaf extract is not among those monograph active ingredients. LCY will not describe it as treating hyperhidrosis or as a drug-like substitute for an antiperspirant.

The narrower phrase “visible signs of perspiration” may describe cosmetic appearance rather than reduced sweat production. That distinction matters: a product can improve perceived wetness, odour or comfort without proving that sweat-gland output has fallen.

What EU claim rules require

EU Regulation 655/2013 requires cosmetic claims to rest on adequate, verifiable evidence and warns against transferring an ingredient’s properties automatically to a finished product. A future deodorant containing KanuFresh would need evidence for its own formula, effective concentration, conditions of use and claimed duration.

Supplier ingredient data can guide development, but the complete product may behave differently because of solvents, fragrance, pH, packaging, application amount and interactions with other ingredients. A launch claim is not a blank cheque for every brand claim.

What the peer-reviewed study does—and does not—show

A 2024 peer-reviewed study indexed in PubMed examined kānuka leaf extract in human keratinocyte and mouse melanoma cell models, focusing on laboratory markers related to moisturisation, oxidative stress, ultraviolet exposure and pigmentation. It did not test people for perspiration, body odour, microbiome balance or deodorant performance.

The paper supports biological interest in the plant, but it cannot validate KanuFresh’s deodorant percentages. One listed affiliation is an ingredient-company connection, which reinforces the need to inspect funding and conflict disclosures before treating the study as independent confirmation.

Safety and limits

Natural origin is not a safety guarantee. FDA consumer guidance says an ingredient’s source does not determine its safety. A finished product still needs appropriate safety substantiation, correct preservation and clear directions. Anyone who develops redness, burning or rash should stop use and seek professional advice when needed.

“Whole-body” or “sensitive area” marketing should never be read as automatic permission for mucosal or genital use. Consumers should follow the exact finished-product label. Persistent or excessive sweating may have medical causes and deserves a health-professional assessment rather than an ingredient trend article.

LCY evidence verdict

Evidence grade: B for the existence, INCI and market positioning of the launch; C for the performance percentages because the underlying supplier studies are not publicly reported in sufficient detail; D for broader mechanism and microbiome implications. The regulatory boundary is high-confidence official evidence.

Commercial disclosure: LifeCareYou has no disclosed commercial relationship with Clariant or Lucas Meyer Cosmetics. This article is not sponsored and contains no affiliate link. It is educational product intelligence, not medical advice or a purchase recommendation.